Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient
The investigators will be retrospectively review the case note of patients registered in the EAP of Nivolumab.

A standard anonymous data collection form will be used to collect data and to analyze it.

Patients with advanced Non-Small Cell Lung Cancer previously treated and included in the SPANISH expanded access programme of nivolumab.
Non Small Cell Lung Cancer
DRUG: Nivolumab 10 MG/ML
Progression Free survival, time from inclusion to progression, At 12 months
Overall Response rate, Percentage of patient reaching a complete, partial or stable disease, At 12 months
This study will help to understand the efficacy of Nivolumab in the real world setting within the SPANISH expanded access programme.

The main objective of this study is to evaluate nivolumab efficacy in terms of Overall Survival (OS), Progression Free Survival (PFS), Overall Response Rate (ORR) and safety in the clinical practice.

The efficacy variables will be assessed for patients (squamous vs non-squamous) who received second line therapies or third lines and subsequent lines and also, long responders will be evaluated.